tbuckley/cabot-search huggingface dataset:
Rates of unacceptable variation (UV) of normal tissue constraints in patients undergoing chest wall/breast and regional nodal irradiation (RNI) in a routine clinical practice.
Authors: Jose Bazan, Dominic DiCostanzo, Lonika Majithia, Allison Marie Quick, Nilendu Gupta, Julia R. White
Journal: Journal of Clinical Oncology (2015)

67 Background: TheNSABP B51/RTOG 1304 clinical trial defines dose-volume constraints for targets/normal tissue receiving RNI. We sought to evaluate UV rate in normal tissue based on the NSABP B51/RTOG 1304 protocol in patients receiving chestwall/breast (CW/B) and RNI in daily practice. Methods: Treatment records of CW/B+RNI patients from 2/2012-5/2015 were studied for: CW or B radiotherapy (RT), RT type (intensity modulated [IMRT] or 3D conformal [3DCRT]), internal mammary node (IMN) inclusion, primary site boost, and nodal boost. No case is enrolled on B51/1304. Dose volume histogram (DVH) was analyzed for the rate of ≥ 1 UV for the following normal tissue constraints: Heart mean dose ≤ 5 Gy; ipsilateral lung (IL): V20 ≤ 35%, V10 ≤ 60%, V5 ≤ 70%; contralateral lung (CL) V5 ≤ 15%; contralateral breast (CB) V4.1 ≤ 5%. Logistic regression is used to test the association between UV and key variables. Results: 203 consecutive cases received CW/B+RNI (105 left, 98 right). RT was to CW in 170 (84%), B in 33 (16%), primary site boost 133 (66%), and IMN 170 (84%). 38 (19%) received IMRT and 14 (6.9%) had a nodal boost. 46 patients (22.6%) had ≥ 1 UV. 19 patients (9.4%) had ≥ 2 UV, all in IMRT patients. 2 patients (1.0%) had a heart UV at 5.2 Gy and 5.6 Gy. The most common UV was CB (n = 32, 15.7%) and IL V5 (n = 22, 10.8%). Higher UV rates are associated with use of IMRT (vs. 3DCRT): 86.8% vs. 7.9%, OR = 77.2 (95% CI 25.7-231.4, p &lt; 0.0001); IMN irradiation: OR = 11.5 (95% CI 1.5-86.8, p = 0.02); and use of nodal boost: OR = 7.4 (95% CI 2.3-23.4, p = 0.001). The most common UVs in IMRT cases are CB (n = 27, 71%), IL V5 (n = 19, 50%), CL V5 (n = 14, 37%) and for 3DCRT are IL V20 (n = 5, 3%), CB (n = 5, 3%) and IL V5 (n = 3, 1.8%). On multivariate analysis, use of IMRT (OR = 64.7, 95% CI 20.8-201.5, p &lt; 0.001) and use of nodal boost (OR = 5.5, 95% CI 1.1-27.1, p = 0.04) but not IMN irradiation (OR = 2.7, 95% CI 0.3-22.0, p = 0.35) were independently associated with higher UV rate. Conclusions: The rate of UV per B51/1304 criteria with 3DCRT in routine clinical practice is low (7.9%). Women treated with IMRT had a significantly higher overall UV rate and clinicians should be aware of this as they initiate treatment planning for RNI.
Phase I/II Clinical Trial of Erwinia Asparaginase (ErwinaseR) in Combination with Prednisolone, Vincristine and Pirarubicin in Children and Young Adults with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
Authors: Chitose Ogawa, Atsushi Manabe, Hiroaki Goto, Katsuyoshi Koh, Daisuke Tomizawa, Keitaro Fukushima, Ken-ichiro Watanabe, Keizo Horibe, Atsushi Kikuta, Mitsuma Hamada, Akira Ohara
Journal: Blood (2014)
Gemtuzumab Ozogamicin in Combination with Attenuated Dose of Standard Induction Chemotherapy Therapy Can Successfully Induce Complete Remission without Increasing Toxicity in Patients with Newly Diagnosed Acute Myeloid Leukemia Aged 55 or Older.
Authors: Ki-Seong Eom, Hee-Je Kim, Chang-Ki Min, Seok Lee, Sung-Yong Kim, Byung-Sik Cho, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park, Chun-Choo Kim
Journal: Blood (2006)
Molecular Cytogenetics Analysis of 13q14 Biallelic Deletion in Chronic Lymphocytic Leukemia: A Study on 250 Patients
Authors: Alessandro Gozzetti, Giulia Papini, Rosaria Crupi, Adele Frasconi, Francesco Forconi, Emanuele Cencini, Donatella Raspadori, Francesco Lauria
Journal: Blood (2011)
Percutaneous biliary drainage in malign obstructive jaundice: Is it really necessary for all patients with malign obstructive jaundice?
Authors: C. Hocazade, I. Akmangit, B. Sever Sayın, M. Doğan, Y. Bozkaya, G.U. Erdem, N. Zengin
Journal: Annals of Oncology (2016)
The Effect of Early High Dose Ara-C in Children with High-Risk Acute Lymphoblastic Leukemia (ALL): Tokyo Children’s Cancer Study Group (TCCSG) Study L99-15.
Authors: Atsushi Manabe, Akira Ohara, Kouichiro Ikuta, Ryouji Hanada, Hiromasa Yabe, Akitoshi Kinoshita, Kenichi Koike, Yuri Okimoto, Yasushi Noguchi, Michiko Kajiwara, Hiroyuki Takahashi, Kanji Sugita, Takashi Fukushima, Keiichi Isoyama, Masahiro Saito, Akira Kikuchi, Setsuo Ota, Masaaki Kumagai, Yasuhide Hayashi, Tomohiro Saito, Masahiro Tsuchida
Journal: Blood (2005)
TRUST: phase II trial of induction chemotherapy (CT) with FOLFOXIRI plus bevacizumab (BV) followed by chemo-radiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC)
Authors: C. Vivaldi, P. Buccianti, G. Musettini, F. Bergamo, M.D. Rizzato, A. Sainato, A. Martignetti, S. Lucchesi, M. Franceschi, C. Boso, F. Pasqualetti, L. Ginocchi, F. Di Clemente, A. Gonnelli, L. Urbani, L. Fornaro, S. Montrone, I. Maretto, R. Balestro, A. Falcone, G. Masi
Journal: Annals of Oncology (2016)
Biodiversity and Topographic Complexity: Modern and Geohistorical Perspectives
Authors: Catherine Badgley, Tara M. Smiley, Rebecca Terry, Edward B. Davis, Larisa R.G. DeSantis, David L. Fox, Samantha S.B. Hopkins, Tereza Jezkova, Marjorie D. Matocq, Nick Matzke, Jenny L. McGuire, Andreas Mulch, Brett R. Riddle, V. Louise Roth, Joshua X. Samuels, Caroline A.E. Strömberg, Brian J. Yanites
Journal: Trends in Ecology & Evolution (2017)
The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+ Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl
Authors: Annette M. Staiger, Marita Ziepert, Heike Horn, David W. Scott, Thomas F. E. Barth, Heinz-Wolfram Bernd, Alfred C. Feller, Wolfram Klapper, Michael Hummel, Harald Stein, Dido Lenze, Martin-Leo Hansmann, Sylvia Hartmann, Peter Moeller, Sergio Cogliatti, Georg Lenz, Lorenz H. Truemper, Markus Loeffler, Norbert Schmitz, Michael Pfreundschuh, Andreas Rosenwald, German Ott
Journal: Blood (2016)
Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15
Authors: Mei Zhou, Jian Luo, Michael Chen, Hong Yang, R. Marc Learned, Alex M. DePaoli, Hui Tian, Lei Ling
Journal: Journal of Hepatology (2017)

Bile acid nuclear receptor farnesoid X receptor (FXR) is a key molecular mediator of many metabolic processes, including the regulation of bile acid, lipid and glucose homeostasis. A significant component of FXR-mediated events essential to its biological activity is attributed to induction of the enteric endocrine hormone fibroblast growth factor (FGF)19 or its rodent ortholog, FGF15. In this report, we compared the properties of human FGF19 and murine FGF15 in the regulation of hepatocarcinogenesis and metabolism in various mouse models of disease.Tumorigenicity was assessed in three mouse models (db/db, diet-induced obese, and multi-drug resistance 2 [Mdr2]-deficient) following continuous exposure to FGF19 or FGF15 via adeno-associated viral-mediated gene delivery. Glucose, hemoglobin A1c and β-cell mass were characterized in db/db mice. Oxygen consumption, energy expenditure, and body composition were evaluated in diet-induced obese mice. Serum levels of alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase were assessed in Mdr2-deficient mice. Expression profiles of genes encoding key proteins involved in bile acid synthesis and hepatocarcinogenesis were also determined.Both FGF15 and FGF19 hormones repressed bile acid synthesis (p<0.001 for both). However, murine FGF15 lacked the protective effects characteristic of human FGF19 in db/db mice with overt diabetes, such as weight-independent HbA1c-lowering and β-cell-protection. Unlike FGF19, FGF15 did not induce hepatocellular carcinomas (HCC) in three mouse models of metabolic diseases (db/db, diet-induced obese, and multi-drug resistance 2 [Mdr2]-deficient mice), even at supra-pharmacological exposure levels.Fundamental species-associated differences between FGF19 and FGF15 may restrict the relevance of mouse models for the study of the FXR/FGF19 pathway, and underscore the importance of clinical assessment of this pathway, with respect to both safety and efficacy in humans.Activation of the nuclear receptor, FXR, leads to the production of a hormone called fibroblast growth factor 19 (FGF19) and subsequently regulation of multiple metabolic processes. Synthetic activators of FXR have been recently approved or are currently in clinical development for treatment of chronic liver diseases, including primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). The safety of these activators was partly assessed in mice exposed for prolonged periods of time. However, the results of this study show that mouse FGF15 and human FGF19 exhibit fundamentally different biological activities in mice. This could raise the concern of relying on rodent models for safety assessment of FXR activators. The potential risk of HCC development in patients treated with FXR agonists may need to be monitored.
Electrophysiological and pharmacological studies on the mechanisms of ventricular tachycardia.
Authors: Shutaro Satake, Fumio Suzuki, Yukio Moroi, Takeshi Endo
Journal: Circulation (1986)

Employing electrophysiological and pharmacological methods, the mechanisms of recurrent ventricular tachycardia were studied in 31 patients, 18 with old myocardial infarction and 13 with idiopathic ventricular tachycardia. In the cases of ventricular tachycardia with old myocardial infraction, the initiation and termination of the tachycardia could be achieved by programmed electrical stimulation in 13 out of 18 patients. Endocardial mapping showed that the earliest excitation site during tachycardia was at the border zone of infarction, where the diastolic fragmented activity was detected. Programmed electrical stimulation sometimes provoked more than two kinds of QRS morphology of tachycardia in the same patient. Class IA antiarrhythmic agents were effective in terminating tachycardia. These data suggest that there are multiple reentrant pathways consisting of partially depressed fast fibers at the border zone of infarction. In the cases with idiopathic ventricular tachycardia, the induction and termination of tachycardia was effected by electrical stimulation in 8 out of 13 patients. For the termination of tachycardia, long overdrive pacing was sometimes necessary. The diastolic fragmented activity could not be detected by endocardial mapping. A class IV drug such as verapamil was more effective for the termination of tachycardia than class I drugs, and there were repetitive short runs of ventricular extrasystole observed until the final termination. These data support the reentrant pathways containing slow with enhanced automaticity as the circuit of idiopathic ventricular tachycardia.
A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.
Authors: Rachel A. Freedman, Ines Maria Vaz Duarte Luis, William Thomas Barry, Ian E. Krop, Nikhil Wagle, Alarice Lowe, Sarah Galler, Jessica Sohl, Steven J. Isakoff, Nadine M. Tung, Eric P. Winer, Nancy U. Lin
Journal: Journal of Clinical Oncology (2014)

TPS668 Background: As a single agent, eribulin is associated with prolonged overall survival compared to treatment of physician’s choice in pts with heavily pre-treated metastatic breast cancer (MBC). In the first-line setting, pertuzumab improves progression-free and overall survival when added to trastuzumab and chemotherapy; however there are limited data in the second line or beyond. This study will evaluate the efficacy of eribulin in combination with trastuzumab and pertuzumab in pts with HER2+ MBC who have progressed after at least 1 line of trastuzumab-based therapy. Methods: This is a single center, single-arm, phase II study. Prior to the start of the phase II study, a safety run-in was conducted and enrolled 6 patients. The established dose of eribulin was 1.4mg/m2 on days 1, 8 of a 21 day cycle. Pts will undergo mandatory metastatic biopsies at baseline and optional biopsies at progression. Circulating tumor cells (CTC) will also be collected. The primary aim is objective response rate, RECIST 1.1. Secondary aims include: (a) Clinical benefit rate, progression free and overall survival (b) safety and tolerability, and (c) mechanisms of response and resistance to HER2-directed therapy, including MET and HER2 co-amplification in CTCs, comparisons of mutational profiles and copy number variation in primary vs. metastatic tumors and in pre-treatment vs. resistant tumors, and exploration of correlations between tumor characteristics and pts outcomes. This is a two-stage Simon Minimax design. In the first stage, 34 pts will be entered. If there are at least 9 responses, the study will continue to the second stage where another 22 pts will be entered. If there are at least 18 responses among the 56 pts, the regimen will be declared worthy of further study. There is a 90% chance of declaring the regimen worthy of further study if the true response rate is 40% and a 10% chance of declaring the regimen worthy of further study if the true response rate is 24% (90% power, 10% Type I error rate). The phase II portion began enrollment in January 2014. The estimated accrual rate is 3-5 patients/month. Clinical trial information: NCT01912963.
Trends in the adoption of robotic technology for radical cystectomy: A population-based analysis.
Authors: Steven Lee Chang, Wei Jiang, Benjamin I. Chung
Journal: Journal of Clinical Oncology (2012)

311 Background: The adoption of the da Vinci Surgical System (Intuitive Surgical, Inc.) for robotic surgery requires a substantial financial investment by hospitals, acquisition of new surgical skills by surgeons, and demand from patients. Although the benefits of this technology have been previously described, the prevalence and adoption rate for robotics in the management of bladder cancer is not currently known. We performed a population-based analysis to determine how the introduction of robotic technology has altered the surgical management of bladder cancer. Methods: We analyzed patient-level data from the Prospective Rx Comparative Database (Premier, Inc., Charlotte, NC), which collects data from over 600 non-federal hospitals throughout the United States. We captured all patients who underwent a radical cystectomy with a diagnosis of bladder cancer between January 1, 2003, and December 31, 2010, based on codes from the International Classification of Disease, 9th edition. Radical cystectomies utilizing the da Vinci Surgical System were identified by a detailed review of the hospital charge data. Results: There was an increase in an overall adoption of robotic radical cystectomy from &lt;2% in 2003 to 23% in 2010. Since 2005, teaching hospitals had a relative increased utilization of robotic radical cystectomy by approximately 40% each year compared to non-teaching hospitals. Hospitals in the West had the highest odds (odds ratio [OR] 3.1, p&lt;0.001 [vs Midwest]) of utilizing robotic surgery for radical cystectomy while larger hospitals (&gt;200 beds) were more likely to adopt robotic technology for radical cystectomy (OR 1.78, p&lt;0.0001). Conclusions: There has been a relatively rapid adoption of the da Vinci Surgical System in the performance of radical cystectomy. This increased utilization is potentially secondary to the acquisition of robotic surgical skills and familiarity with transperitoneal pelvic anatomy following the widespread use of robotic technology for radical prostatectomy during the same time period.
Sentinel lymph node biopsy (SNB) in pregnancy-associated breast cancer (PABC).
Authors: Adrienne Gropper, Katherina Zabicki Calvillo, Susan Troyan, Laura Stewart Dominici, Esther Rhei, Katherine E. Economy, Lidia Schapira, Nadine M. Tung, Jane L. Meisel, Ann H. Partridge, Erica L. Mayer
Journal: Journal of Clinical Oncology (2013)

1117 Background: SNB in PABC is not often pursued due to concerns for potential fetal harm. There are only limited data available regarding the safety and efficacy of SNB in patients (pts) with PABC. Methods: Pts with PABC who underwent SNB were identified from within an existing multi-institutional PABC cohort diagnosed 1996-2013. Factors evaluated included method and result of SNB evaluation, maternal disease outcome, and fetal outcomes. Results: Within a cohort of 78 PABC pts, 53 had breast surgery while pregnant; 23 (43%) underwent SNB, 27 (51%) underwent initial axillary node (AN) dissection, 18 of whom were clinically node negative, and 3 had no nodal evaluation. Of SNB pts, 21 (91%) had stage 1-2 disease; 14 (61%) had ER/PR+ disease and 7 (30%) HER2+. Eight (35%), 9 (39%), and 6 (26%) women had SNB in the first, second, and third trimesters, respectively. 99-Technetium-labelled sulfur colloid (99-Tc) alone was used for SNB in 14 pts; methylene blue (MB) dye alone was used in 7. SN was identified in 100% of pts; see Table. There were no SNB-associated complications. At a median of 2.4 years from diagnosis, there were no locoregional recurrences, 3 (13%) distant recurrences, and 1 (4%) death from breast cancer. Among pts who underwent SNB, there were 20 liveborn infants and 3 pregnancies ongoing. Of the 20 infants born, 18 were healthy, 1 unknown, and 1 had cleft palate (in setting of maternal risk factors including smoking and methadone). Conclusions: SNB in PABC appears to be a safe and accurate procedure using either 99-Tc or MB techniques. This is one of the largest experiences reported to date of SNB during PABC; however, numbers remain limited and rates of SNB in our cohort were lower than current rates in non-PABC patients. Additional research and monitoring for safety of this procedure is warranted in women with PABC. [Table: see text]
A Distinct Pattern of Non-HLA Polymorphisms Predicts an Increased Risk for GvHD without Benefit of GvL in HLA Matched Sibling Transplants for Chronic Myeloid Leukemia (CML).
Authors: Anne M. Dickinson, Kim F. Pearce, Jean Norden, A. Neylor, Ernst Holler, Vanderson Rocha, Eliane Gluckman, Hans-Jochem Kolb, Ilona Hromadnikova, Petr Sedlacek, Dietger W. Niederwieser, Ronald Brand, Tapani Ruutu, Jane Apperley, E.A.J.M. Goulmy, Eduardo Olavarria, T.M. de Witte, Eddy Roosnek, Wolfgang Siegert, Alois Gratwohl
Journal: Blood (2006)
Development of RAD51 as Biomarker for Sensitivity to the Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma.
Authors: Sriram Balasubramanian, Shanthi Adimoolam, Mint Sirisawad, Andrew M. Evens, Leo I. Gordon, Richard Miller, Joseph J. Buggy
Journal: Blood (2007)
TIMP-1 and TIMP-2 Levels Are Directly Correlated with Neoangiogenesis and Are Prognostic Factors in Multiple Myeloma Patients.
Authors: Luciana Correa Oliveira de Oliveira, Juliana Alves Uzuelli, Ana Paula Alencar de Lima Lange, Barbara Amelia Aparecida Santana-Lemos, Marcia Sueli Baggio, Aglair Bergamo Garcia, Leonardo Carvalho Palma, Ana Maria Anselmi Dorigan, Jose Eduardo Tanus Santos, Fabiano Pinto Saggioro, Fernando Chahud, Eduardo Magalhaes Rego
Journal: Blood (2009)
Bortezomib + DA-EPOCH-R Induction Therapy Followed by Maintenance Bortezomib Versus Observation in Newly Diagnosed Mantle Cell Lymphoma
Authors: Kieron Dunleavy, Cliona Grant, Julieanne Hessler, Barry W. Miller, Seth M. Steinberg, Stefania Pittaluga, Mark Roschewski, Elaine S. Jaffe, Adrian Wiestner, Wyndham H. Wilson
Journal: Blood (2012)
Unveiling of HIV dynamics among transgender women: a respondent-driven sampling study in Rio de Janeiro, Brazil
Authors: Beatriz Grinsztejn, Emilia M Jalil, Laylla Monteiro, Luciane Velasque, Ronaldo I Moreira, Ana Cristina F Garcia, Cristiane V Castro, Alícia Krüger, Paula M Luz, Albert Y Liu, Willi McFarland, Susan Buchbinder, Valdilea G Veloso, Erin C Wilson
Journal: The Lancet HIV (2017)
The Role of Coronary Artery Bypass Grafting in ST-Segment Elevation Myocardial Infarction : a Substudy From the Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Myocardial Infarction Study
Authors: Youlan L. Gu, Iwan C. van der Horst, Yvonne Douglas, Tone Svilaas, Felix Zijlstra
Journal: Journal of the American College of Cardiology (2009)
Interruption of the IFN γR/CXCR3 Axis Results in Altered T Cell Trafficking In Vivo and Abrogation of GvHD While Maintaining a Robust Gvl Response
Authors: Jaebok Choi, Edward Dela Ziga, Julie Ritchey, Julie Prior, Lynne Collins, Johnny Wei, David Piwnica-Worms, John F. DiPersio
Journal: Blood (2011)
Intravenous Immunoglobulin (Privigen®) Has Similar Pharmacokinetic Properties in Primary and Secondary Immunodeficiency
Authors: Michael Tortorici, John-Philip Lawo, Jeanine Jochems, Shilpa Puli, Jutta Hofmann, Dietmar Pfruender, Mikhail Rojavin
Journal: Journal of Allergy and Clinical Immunology (2017)
201P POU5F1 gene expression in colorectal cancer: a novel prognostic marker after curative surgical resection
Authors: N. Miyoshi, M. Ohue, M. Yasui, S. Fujino, K. Sugimura, A. Tomokuni, H. Akita, S. Kobayashi, H. Takahashi, T. Omori, H. Miyata, Y. Fujiwara, M. Yano
Journal: Annals of Oncology (2016)
Tracing the Medicinal Acceptance of <i>Aloe Vera</i>
Authors: Vincent M. Hsu, Adam S. Aldahan, Vidhi V. Shah, Stephanie Mlacker, Keyvan Nouri
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics
Authors: C. Lepage, J.-M. Phelip, L. Cany, E. Maillard, A. Lievre, T. Chatellier, R. Faroux, J.-C. Duchmann, M. Ben Abdelghani, G. Breysacher, P. Geoffroy, D. Pere-Verge, A. Pelaquier, D. Pillon, J. Ezenfis, Y. Rinaldi, A. Darut-Jouve, M. Duluc, A. Adenis, O. Bouché
Journal: Annals of Oncology (2016)
MRD-Based Strategy without Myeloablative Transplantation for AML in Children
Authors: Akihisa Sawada, Sadao Tokimasa, Masahiro Yasui, Maho Koyama-Sato, Mariko Shimizu, Kohei Higuchi, Azusa Mayumi, Aya Ioi, Keisei Kawa, Masami Inoue
Journal: Blood (2015)
Model-Informed Drug Development for Malaria Therapeutics
Authors: Kayla Ann Andrews, David Wesche, James McCarthy, Jörg J. Möhrle, Joel Tarning, Luann Phillips, Steven Kern, Thaddeus Grasela
Journal: The Annual Review of Pharmacology and Toxicology (2017)

Malaria is a critical public health problem resulting in substantial morbidity and mortality, particularly in developing countries. Owing to the development of resistance toward current therapies, novel approaches to accelerate the development efforts of new malaria therapeutics are urgently needed. There have been significant advancements in the development of in vitro and in vivo experiments that generate data used to inform decisions about the potential merit of new compounds. A comprehensive disease-drug model capable of integrating discrete data from different preclinical and clinical components would be a valuable tool across all stages of drug development. This could have an enormous impact on the otherwise slow and resource-intensive process of traditional clinical drug development.